Revolution Medicines’ daraxonrasib posted a major survival benefit in a Phase 3 pancreatic cancer trial, strengthening the case for a new class of KRAS-targeted therapies in a disease that historically resists durable responses. In the study discussed by STAT, patients with advanced pancreatic adenocarcinoma receiving the daily oral pill lived a median of 13.2 months versus 6.7 months with standard chemotherapy. The company said it plans to use the data to pursue FDA approval, with timing potentially improving if the agency fast-tracks the file. Investigator commentary highlighted the trial readout as the latest proof that modern KRAS biology-driven strategies can translate into clinically meaningful outcomes. STAT’s reporting also situates the result in the broader KRAS race that began after academic work clarified druggable KRAS mutant subsets. Early first-generation approaches disappointed due to rapid resistance, but the field has since accelerated with multiple KRAS inhibitors now in clinical testing. For the oncology pipeline, the key industry implication is durability and potential breadth: KRAS alterations also occur across multiple solid tumors, raising the prospect of follow-on trials beyond pancreatic cancer if the FDA review confirms benefit-risk.